Multidose Botulinum Toxin A for Intralaryngeal Injection: A Cost Analysis

Area of Science:

• Otolaryngology
• Pharmacoeconomics
• Neurology

Background:

• Botulinum toxin A (BtxA) is a primary treatment for laryngeal dystonias.
• Current BtxA product labeling and insurance mandates often lead to single-use vial protocols, despite evidence supporting multidose use.
• This practice creates significant financial burdens in healthcare.

Purpose of the Study:

• To compare the cost-effectiveness of multidose versus single-use botulinum toxin A (BtxA) for treating laryngeal dystonias.
• To analyze projected cost savings for the healthcare system.

Main Methods:

• A retrospective review of patient records and billing information was conducted for intralaryngeal BtxA injections.
• Cost analysis was based on the price of a 100-unit vial of BtxA ($670) and billed units.
• Inclusion criteria focused on specific CPT codes (64617, J0585).

Main Results:

• A single-use vial approach for BtxA treatment resulted in an estimated cost of $2,050 per patient annually.
• A multidose approach, billed per unit with wastage charges, reduced the yearly cost to $168 per patient.
• This represents a 1,118% price increase for the single-use method compared to multidose use.

Conclusions:

• Multidose botulinum toxin A (BtxA) application, billed per unit, is substantially more economical than single-use vial billing.
• Adopting a multidose strategy can yield significant cost savings for the healthcare system.
• This approach maintains safety and effectiveness in treating laryngeal dystonias.